Literature DB >> 25599668

Diagnosing lysosomal storage disorders: mucopolysaccharidosis type I.

Britt A Johnson1, Angela Dajnoki1, Olaf A Bodamer1.   

Abstract

Mucopolysaccharidosis type I (MPS I) is a lysosomal storage disorder due to deficiency of alpha iduronidase (IDUA). Progressive storage of dermatan and heparan sulfate throughout the body lead to a multiorgan presentation including short stature, dysostosis multiplex, corneal clouding, hearing loss, coarse facies, hepatosplenomegaly, and intellectual disability. Diagnosis of MPS I is based on IDUA enzyme analysis in leukocytes or dried blood spots (DBS) followed by molecular confirmation of the IDUA gene mutations in individuals with low enzyme activity. The advent of mass spectrometry methods for enzyme analysis in DBS has enabled high-throughput screening for MPS I in symptomatic individuals and newborn infants. The following unit provides the detailed analytical protocol for measurement of IDUA activity in DBS using tandem mass spectrometry.
Copyright © 2015 John Wiley & Sons, Inc.

Entities:  

Keywords:  Hurler Syndrome; MPS I; Mucopolysaccharidosis type I; Scheie Syndrome; alpha-iduronidase; dried blood spot; tandem mass spectrometry

Mesh:

Substances:

Year:  2015        PMID: 25599668     DOI: 10.1002/0471142905.hg1717s84

Source DB:  PubMed          Journal:  Curr Protoc Hum Genet        ISSN: 1934-8258


  4 in total

1.  Chiari I malformation and syringomyelia in mucopolysaccharidosis type I (Hurler syndrome) treated with posterior fossa decompression: Case report and review of the literature.

Authors:  Vyacheslav Makler; Christina L Goldstein; Daniel Hoernschemeyer; Tomoko Tanaka
Journal:  Surg Neurol Int       Date:  2017-05-26

Review 2.  International working group identifies need for newborn screening for mucopolysaccharidosis type I but states that existing hurdles must be overcome.

Authors:  Rossella Parini; Alexander Broomfield; Maureen A Cleary; Linda De Meirleir; Maja Di Rocco; Waseem M Fathalla; Nathalie Guffon; Christina Lampe; Allan M Lund; Maurizio Scarpa; Anna Tylki-Szymańska; Jiří Zeman
Journal:  Acta Paediatr       Date:  2018-10-23       Impact factor: 2.299

3.  A Biochemical Platform to Define the Relative Specific Activity of IDUA Variants Identified by Newborn Screening.

Authors:  Seok-Ho Yu; Laura Pollard; Tim Wood; Heather Flanagan-Steet; Richard Steet
Journal:  Int J Neonatal Screen       Date:  2020-11-12

4.  Case Report: Cerebral Revascularization in a Child With Mucopolysaccharidosis Type I.

Authors:  Nathan Grant; J Michael Taylor; Zach Plummer; Kasiani Myers; Thomas Burrow; Lori Luchtman-Jones; Anna Byars; Adrienne Hammill; Katie Wusick; Edward Smith; James Leach; Sudhakar Vadivelu
Journal:  Front Pediatr       Date:  2021-06-10       Impact factor: 3.418

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.